> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By HotStockRockets | Friday 14 September 2018
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Having filed patents and announced the start of the technology programme last year, Cambridge Cognition (COG) has now announced its “first voice-based cognitive assessments are available for use in its core pharmaceutical and biotechnology clinical trial channels”…
It emphasises its NeuroVocalix platform’s “ability to use AI to derive voice biomarkers, which can objectively measure mental states” and that “this broadly applicable machine-learning platform is already generating interest from digital health companies specialising in areas ranging from pain to Parkinson's disease and psychiatry with the first commercial partnerships expected in 2018”.
The shares declined to hit 120p last month and are currently at just over 130p. We tipped at 145p – noting the real excitement is in the digital, and particularly that it has “driven testing closer to the patient using wearable and voice activated technologies” – and their IP-rooted high margins, and looked for gains from positive take-up news flow and a return to profit. With this latest boosting our hopes on the former and operational gearing, we remain optimistic.
Since our tip also, we note house broker finnCap has increased its price target to 175p – and we continue to believe the broker numbers may well prove conservative. As such, at up to 155p, the stance remains buy.
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments are turned off for this article.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen